Health & Biotech
mTOR drug shows reverse ageing may be possible. Here’s where it puts ASX-listed PharmAust
Health & Biotech
PharmAust’s interim analysis to point the way forward for MND trial
Health & Biotech
Argenica achieves Phase 1 trial success as it works to reduce brain tissue death
Health & Biotech
Nanollose files patent for breakthrough in microbial cellulose technology
Health & Biotech
Creso Pharma advances its footprint across Asia Pacific with its line of animal care products
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as Proteomics inks Sonic deal
Health & Biotech
ASX Health Stocks: Weed stock Epsilon sees growing demand for cannabis, gets licence renewal in Australia
Health & Biotech
ASX Health Stocks: A good day for women’s healthcare with big news from HeraMED and Ecofibre
Health & Biotech
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
Health & Biotech
Creso’s Groupon deal and mushroom launch pumps potential US market size
Health & Biotech
PharmAust says its MPL drug has a long and stable shelf life
Health & Biotech
EZZ enters new distribution partnership to extend foothold in China projected to boost revenue by $16 million annually
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.